Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia

Authors not listed

Animuscure Inc. · 2025

Dysbiosis Human Randomized controlled trial

Abstract

This clinical trial aims to find out whether AMC6156 can improve physical function and is safe in older adults with sarcopenia. Participants will take AMC6156 or a placebo daily for 12 weeks, and their movement, strength, and safety will be regularly monitored through tests and checkups.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-23 MST

Cite this

APA

Anonymous. (2025). A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia. <em>Animuscure Inc.</em>. https://clinicaltrials.gov/study/NCT07072195

Vancouver

Anonymous. A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia. Animuscure Inc.. 2025.

BibTeX

@misc{anon2025AMulti, title = {A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia}, author = {Anonymous}, journal = {Animuscure Inc.}, year = {2025}, }